BackAbattis Bioceuticals Overview

Abattis Bioceuticals Long Term Debt

Latest long-term debt for ATTBF: $120K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$123723.00

Peer average

Loading

Abattis Bioceuticals Long Term Debt History

Loading

Abattis Bioceuticals vs. peers: Long Term Debt Comparison

Loading

Abattis Bioceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Abattis Bioceuticals (ATTBF) FAQ

Abattis Bioceuticals (ATTBF) currently reports a long-term debt of $120K as of September 2019. In the prior-year period, the figure was $0. Use the charts on this page to explore Abattis Bioceuticals's long-term debt history and peer comparisons.

Abattis Bioceuticals's long-term debt changed from $0 to $120K (period ending September 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Abattis Bioceuticals reported $120K in long-term debt as of September 2019. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $120K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Abattis Bioceuticals, and consider following ATTBF for alerts when major investors trade the stock.

Abattis Bioceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $120K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATTBF with unrelated industries.